September 18, 2025

Newly-engineered angiopoietin-1 as a cell-priming agent for CVD

View Full Paper

Ask AI

Bookmark

FVA3-Ang1 significantly improved engraftment and tissue regeneration in cardiovascular disease models.
Gene expression analysis revealed a shift towards endothelial lineage after 24 hours of PBSC priming.
FVA3-Ang1 outperformed naive Ang1 in enhancing the activity of endothelial cells and signaling pathways.
A clinical trial is currently assessing the safety and efficacy of FVA3-Ang1-primed PBSC infusion.

Discussion

No takes yet. Share an insight, caveat, or question.

Engineering angiopoietin-1 improves gene expression in endothelial cells, indicating enhanced PBSC potential.

Kang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark